Response to “Comment on: ‘When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council’” - 16/07/18
Doi : 10.1016/j.jaad.2018.03.048
Eric L. Simpson, MD, MCR a, ⁎ 
, Nick J. Reynolds, MD, FRC b, Carsten Flohr, MD, PhD, MSc c, Amy S. Paller, MSc, MD d, e, f, Jonathan I. Silverberg, MD, PhD, MPH d, g, h, Michel J. Cork, PhD, FRCP i, Emma Guttman-Yassky, MD, PhD j, Alan D. Irvine, MD, DSc k
, Nick J. Reynolds, MD, FRC b, Carsten Flohr, MD, PhD, MSc c, Amy S. Paller, MSc, MD d, e, f, Jonathan I. Silverberg, MD, PhD, MPH d, g, h, Michel J. Cork, PhD, FRCP i, Emma Guttman-Yassky, MD, PhD j, Alan D. Irvine, MD, DSc k a Department of Dermatology, Oregon Health & Science University, Portland, Oregon
b Newcastle National Institute for Health Research Biomedical Research Centre and Medical Research Council/Engineering and Physical Sciences Research Council Molecular Pathology Node, Newcastle University and Royal Victoria Infirmary, Newcastle upon Tyne, Newcastle, United Kingdom
c Unit for Population-Based Dermatology Research, St. John's Institute of Dermatology, King's College London and Guy's & St. Thomas' National Health Service Foundation Trust, London, United Kingdom
d Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois
e Department of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois
g Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
h Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois
f Department of Pediatrics, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
i Sheffield Dermatology Research Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, United Kingdom
j Icahn School of Medicine at Mount Sinai Medical Center, New York, New York
k Trinity College Dublin, National Children's Research Centre, Paediatric Dermatology, Our Lady's Children's Hospital, Dublin, Republic of Ireland
∗Correspondence to: Eric L. Simpson, MD, MCR, Oregon Health and Science University, 3303 SW Bond Ave, CH16D, Portland, OR 97225Oregon Health and Science University3303 SW Bond AveCH16DPortlandOR97225
Il testo completo di questo articolo è disponibile in PDF.
| Funding sources: Corporate sponsorship was provided to the International Eczema Council by Abbvie, Amgen, Celgene, Chugai, Galderma, Glaxo-SmithKline/Stiefel, the Leo Foundation, Leo Pharma, Lilly, MedImmune/Astrazeneca, Pfizer, Sanofi, Genzyme and Regeneron Pharmaceuticals, and Valeant. The cost of publication was covered by the International Eczema Council. |
|
| Disclosure: Dr Simpson is an investigator for Eli Lilly and Company, Leo, AbbVie, GlaxoSmithKline, Regeneron, Novartis, Vanda, and Tioga and a consultant with honorarium for Eli Lilly and Company, Celgene, Dermira, Leo, AbbVie, Glaxo Smith Kline, Pfizer, Regeneron, and Menlo Therapeutics. Dr Reynolds is an investigator for Biotechnology and Biological Sciences Research Council Case with Stiefel/GSK, Innovate UK and Stiefel/GSK, Genentech, Biotechnology and Biological Sciences Research Council Case with AstraZeneca, and Bristol-Myers Squibb and a consultant with honorarium for Genentech. Dr Flohr is a consultant with honorarium for Sanofi and Genentech. Dr Paller is an investigator for Galderma, Leo Foundation, Leo Pharmaceuticals, Incyte Corporation, and Regeneron-Sanofi and a consultant with honorarium for AbbVie, Dermira, Eli Lilly and Company, Expanscience, GSK-Stiefel, Menlo Therapeutics, Novartis, Pfizer, Sanofi-Regeneron, and Valeant. Dr Cork is an investigator for Leo, Sanofi, and Regeneron, and he has received a symposium grant from Sanofi and served as a consultant with honorarium for Regeneron, Sanofi, Novartis, and L'Oreal. Dr Guttman-Yassky is an investigator for Celgene, Dermira, Glenmark, Pfizer, Janssen Biotech, Novartis, DBV/Innovaderm, Leo Pharma, Merck Pharma, Regeneron, BMS, Immune, Eli Lilly and Company, MedImmune, Vitae, UCB, Galderma, AbbVie, Asana, Sienna, Regeneron, AntibioTx/Innovaderm, and Novan and a consultant with honorarium for Allergan, Escalier, SunPharma, Arena, AbbVie, Anacor, Celgene, Pfizer, Regeneron, Sanofi, Dermira, GlaxoSmithKline, Vitae, Eli Lilly and Company, BMS, Galderma, Genentech, Glenmark, Leo Pharma, and Novartis. Dr Irvine is a consultant with honorarium for Sanofi Regeneron, AbbVie, Genentech, Anacor, and Chugai Pharma. Dr Silverberg has no conflicts of interest to disclose. |
|
| The sponsors had no influence on the content and viewpoints in this article. |
© 2018
American Academy of Dermatology, Inc.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 79 - N° 2
P. e25-e26 - agosto 2018 Ritorno al numero
Articolo precedente
- Comment on: “When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council”
- Adam Daunton, Jonathan M.R. Goulding
- Bullous pemphigoid and diabetes mellitus: Are we missing the larger picture?
- Shamir Geller, Noa Kremer, Tal Zeeli, Eli Sprecher
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?